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I. INTRODUCTION
In the field of cardiology, large-scale clinical trials and
registries have provided a wealth of data on hundreds of
thousands of patients. This is especially true in the field of
acute coronary syndromes (ACS), which range from ST-
segment elevation myocardial infarction (STEMI) to non–
ST-segment elevation MI (NSTEMI) to unstable angina
(UA). These data have been used to define new therapies
and to guide clinical care through evaluation of both the
process and the quality of care and outcomes for patients
with ACS.
The American College of Cardiology (ACC) recognizes
the importance of using clinical data and has established a
data set and launched the National Cardiovascular Data
Registry (NCDRTM), a national, voluntary registry of car-
diac catheterization and percutaneous coronary intervention
(PCI) procedures. Several national and international regis-
tries have adopted many of the elements and definitions
contained in the ACC-NCDRTM Cath Lab Module ver-
sion 2.0 (1), thus providing the potential for more reliable
comparisons across registries. Given the ACC’s recognition
of the importance of standardizing a common lexicon for
describing the clinical management and outcomes of pa-
tients with a variety of conditions, the ACC has expanded
its role to include the development of clinical data standards.
A. Organization of Writing Committee and Methods for
Developing the ACS Clinical Data Standards
The process undertaken in developing these clinical data
standards began with the ACC Task Force on Clinical Data
Standards, which identified ACS as an important area in
which to standardize definitions. A writing committee was
formed that included a select group of 10 physicians who
have been involved in large-scale ACS clinical trials and
other registries and who were recognized experts in the
field. Additionally, the writing committee included mem-
bers who had expertise in developing performance measures
for patients with acute myocardial infarction. Finally, this
group included several international members to ensure
balance in the selection of data elements for the type of
practice worldwide that would be reflected by the data
elements and definitions recommended in these standards.
Toward that end, an informal collaboration with the Euro-
pean Society of Cardiology (ESC) was established.
The subcommittee met several times over a period of 2
years to refine the data standards to their present form. The
overriding goals were to focus on important variables
needed to assess the characteristics of patients, their treat-
ment with both medication and interventional therapies,
and their outcomes. In developing the list, the writing
committee balanced completeness with length and thus
tried to be as concise as possible to facilitate use of these
variables by others in an actual registry or trial setting.
Standardized definitions for each variable are provided. For
these, the writing committee again balanced greater speci-
ficity of definitions against what information can readily and
reliably be obtained from medical records to make these
definitions functional in the various real-world settings in
which they may be used.
Writing committee members compiled and reviewed case
report forms, data elements, and definitions from national
or international ACS registries and previous or ongoing
clinical trials to develop an initial set of data elements.
Examples of these data sources include the ACC-
NCDRTM (2), the National Registry of Myocardial Infarc-
tion (NRMI) (3), the Global Registry of Acute Coronary
Events (GRACE) (4), and the Monitoring Trends and
Determinants of Cardiovascular Disease (MONICA) (5),
as well as the Thrombolysis in Myocardial Infarction
(TIMI) (6–8), and the Global Use of Streptokinase and
Tissue Plasminogen Activator to Open Occluded Arteries
(GUSTO) (9–11) trials.
The data elements reflected an ongoing review of the
medical literature to focus on new developments. Current
scientific evidence provided the basis for the selection and
definition of appropriate data elements required to evaluate
and manage patients with ACS. Therefore, data elements
and definitions were linked whenever possible to evidence-
based national guidelines. For the purposes of these clinical
data standards, the writing committee chose to review and
reference several ACC/American Heart Association (AHA)
guidelines, including but not limited to the ACC/AHA
Guidelines for the Management of Patients With Acute
Myocardial Infarction (12) and the ACC/AHA Guidelines
for the Management of Patients With Unstable Angina/
Non–ST-Segment Elevation Myocardial Infarction (13). In
addition, the writing committee reviewed the Management
of Acute Coronary Syndromes: Acute Coronary Syndromes
Without Persistent ST-segment Elevation: Recommenda-
tions of the Task Force of the European Society of Cardi-
ology (14) and adopted the definition of myocardial infarc-
tion (MI) as recently published in an ESC/ACC consensus
document on the redefinition of MI (15). On a few
occasions, data elements and definitions were linked to other
national guidelines, such as the National Cholesterol Educa-
tion Program (NCEP III) guidelines (16).
Finally, the committee members reviewed the list of data
elements bearing in mind the intent of their use. For
example, some data elements can be used for risk adjust-
ment, others can be used to construct performance mea-
sures, and several elements can be used for multiple pur-
poses. Additional uses include patient demographics, health
services research, follow-up, and outcomes analysis.
The ACC Key Elements and Data Definitions for
Measuring the Clinical Management and Outcomes of
Patients With Acute Coronary Syndromes was reviewed by
4 official reviewers nominated by the ACC, the ACC/AHA
Task Force on Performance Measures, the NCDR Planning
and Management Task Force, and 3 outside content review-
ers. To increase its applicability further, the document was
posted on the ACC World Wide Web site for a 30-day
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public comment period, and the comments were used to
develop the final version. This document was approved for
publication by the ACC governing body and was formally
endorsed by the American Association of Cardiovascular
and Pulmonary Rehabilitation, American College of Emer-
gency Physicians, American Heart Association, Cardiac Soci-
ety of Australia & New Zealand, National Heart Foundation
of Australia, Society for Cardiac Angiography and Interven-
tions and the Taiwan Society of Cardiology. This document
will be considered current until the Task Force on Clinical
Data Standards revises or withdraws it from distribution.
The document is presently divided into 3 sections:
● Introduction: A description of the methodology of devel-
oping the ACS Clinical Data Standards and intended
goals for their use.
● Data Elements and Definitions: A listing of key data
elements and definitions.
● Reference Guide: A multipurpose resource that maps
common data fields between ACS core data elements and
other national/regional data registries, links ACS core
data elements to relevant ACC/AHA guidelines, and
identifies potential uses for each core element.
The Introduction and Data Elements and Definitions
sections are published in the December issue of the Journal
of the American College of Cardiology. The Reference
Guide is available online at www.acc.org.
B. Purpose of the ACS Clinical Data Standards
There are many goals that this project hopes to fulfill by
providing a list of key data elements and standardized
definitions in ACS (Table 1). First, it is hoped that
standardized definitions will allow better cross-comparison
of results and clinical outcomes between different trials and
registries. This would be particularly true for meta-analyses
of trials, where differences in data collection methods and in
definitions have hampered the validity of these analyses.
Furthermore, the standardized definitions should also facil-
itate the research that comes from the trials and registries,
because the key elements needed for assessment of efficacy
and safety and for appropriate risk adjustment would be
included in the clinical data standards.
Second, the provision of a list of the major variables,
outcomes, and definitions in ACS should facilitate the
development and conduct of future registries at both indi-
vidual hospital and national levels. In fact, the ACS Clinical
Data Standards could be used in their entirety to develop a
registry. For example, GRACE includes nearly all (104
elements) of the data elements included in this document
(17). Alternatively, subsets of the data could be used if a
more focused registry were to be performed, for example,
one that evaluated the use of only patients with MI
(STEMI or NSTEMI) but did not include UA patients,
such as the NRMI (3). To a greater degree, if a given
hospital wanted to perform a quality-improvement effort to
reduce door-to-drug time (18), the list might be restricted
to only 10 to 20 variables.
Third, the use of standardized definitions and registry
data should facilitate quality improvement. Information on
these data elements that is collected as part of a quality-
improvement program at a hospital, state, or national level
should provide the means to assess quality of care (both the
process of care and clinical outcomes) and thereby facilitate
improvements.
Fourth, these data elements and definitions can be used
to assess performance measures that could facilitate im-
provement in quality of care on a population-wide basis by
identifying underuse, overuse, or misuse of therapies
(19,20). For example, they could be used to compare
subgroups of patients with regard to the various perfor-
mance measures and to identify certain subgroups in whom
medications are underused (e.g., women) (21).
Finally, the list of data elements could become the basis
for a standardized charting process with the anticipation
that medical charting will progressively move toward an
electronic format.
C. General Considerations of the ACS Clinical Data
Standards
1. Data Elements. The writing committee paid close
attention to the level of detail of the information provided
about certain variables, such as timing of prior cardiovascu-
lar events, timing of procedures, exact drug names vs. classes
of drugs, and types of insurance. For these or any of the data
elements listed, one can always decide to collect more or less
information. For example, if a hospital association were
compiling a registry on patient insurance status vs. cardiac
procedures and outcomes, the group might use more sub-
categorizations than listed here. On the other hand, if a
pharmaceutical company were doing a study to evaluate a
new drug in UA, the type of insurance might not matter and
could be omitted. A third example is a community hospital
that wishes to track its use of new therapies, such as the
glycoprotein IIb/IIIa inhibitors, for which as few as 10 of
the listed elements might be collected on patients.
These data elements could also be expanded to include
additional information, such as individual listing of all the
relative contraindications to aspirin or beta-blockers, for
careful measurement of performance measures, as was done
in the Cooperative Cardiovascular Project (19). Expansion
of the variables collected would also be expected in the
Table 1. Goals of the American College of Cardiology Listing
of Acute Coronary Syndrome Data Elements and Standardized
Definitions
1. Facilitate data management in future trials and registries
2. Allow for more reliable comparisons of results between trials and
registries
3. Facilitate clinical research
4. Allow for better quality-of-care assessment and improvement
programs
5. Allow for development of performance measures
6. Facilitate possible transition to electronic medical records
2116 Cannon et al. JACC Vol. 38, No. 7, 2001
ACC Clinical Data Standards December 2001:2114–30
setting of a randomized clinical trial of a new drug, for
which additional information would be required regarding
study procedures and drug therapies. Thus, depending on
the intended use of the variables, one could restrict or
expand the number of data elements used. In either case, the
definitions provided in this document should assist in
standardizing the process.
2. Medication Use. Because medical therapies have such
an important effect on the outcomes of patients with ACS,
the proposed data elements and definitions are relatively
detailed in tracking medication use. Specifically, it is pro-
posed that data on the types of medications be collected at
a minimum of 3 time points: before the acute event, the first
24 hours after the event, and at hospital discharge. In
addition, antithrombotic therapies for PCI are included in
this list. Furthermore, in cases in which there may be
differences between drugs within a class, it is proposed that
information on the exact brand be collected. One potential
means of doing this efficiently in a registry is to use a coding
system in which the data element (for example, for glyco-
protein IIb/IIIa blockers) is not a check box of yes/no but
rather a field in which a number (e.g., 0, 1, 2, or 3) is entered
that represents a specific drug. In this fashion, space can be
conserved on a registry form, but detailed information
becomes available about the exact type of drug used. In
addition, when new drugs become approved for use, they
can simply be added to the definition as an extra number on
the list, but no change is necessary in the data field itself on
the registry form. Finally, as new classes of drugs become
available, these would need to be added to the proposed list
of medications.
3. Risk Adjustment and Outcomes. The list of data
elements includes factors included in some of the major risk
models, notably those developed in the GUSTO-I trial (22)
and those from TIMI (23,24) and others (25). Outcomes
can be adjusted for differences in patient characteristics and
to allow better comparisons across hospitals, treatment
strategies, and subgroups of patients. However, although
the important data elements needed for risk adjustment
have been included, not all of the more minor aspects
needed for very detailed risk assessment or patient subset
assessment have been included. Notably, relative contra-
indications to some medications (for example, a history of
retinal bleeding for use of aspirin or a prior history of
liver dysfunction for the use of statins) were not included
in an effort to keep the list of elements as streamlined as
possible.
Cost-effectiveness of new (and old) therapies and treat-
ment strategies is of growing importance (26–30). This data
set includes items to allow estimation of resource utilization,
which will allow estimation of cardiovascular costs.
Finally, many outcomes are included in the list of data
elements. These are important for the evaluation of the clinical
benefits and risks of medical and interventional therapies.
With regard to the definition of MI, the Committee adopted
the ESC/ACC definition of MI (15) with expansion of the
definition detail to match current clinical trials (6–11). The
standard cutpoint of CK-MB greater than or equal to 3 times
the upper limit of normal following PCI was adopted (10,29).
New data on the definition of MI following CABG was used
as well (31). However, the data set recommends that all serial
cardiac markers (CK-MB, CK, troponin) during the hospital-
ization be collected so that other thresholds could be applied.
However, the data set recommends that all serial cardiac
markers (CK-MB, CK, troponin) during the hospitalization
be collected so that the other thresholds could be applied.
Some of the data elements listed would potentially
require review by a physician (for example, final diagnosis of
the admission event—UA vs. MI vs. noncardiac chest
pain—or the assessment of coronary flow at cardiac catheter-
ization) (31). However, the vast majority of data elements have
simple definitions that the writing committee believes can be
extracted from a standard medical chart.
In conclusion, the writing committee hopes that the
attached set of data elements and definitions for patients
with ACS will help facilitate research and assessment of
quality of care and thereby advance the practice of medicine.
II. DEFINITIONS
ELEMENT DEFINITION
Baseline Characteristics
Gender Patient’s gender: male or female
Date of birth Day, month, and year of the patient’s birth
Race Patient’s race:
1. White
2. Black
3. Hispanic
4. Asian
5. Native American
6. Other race not llisted
(Note: These categories could be used in a “check all that apply” format to identify mixed races.)
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ELEMENT DEFINITION
Insurance Four broad types of insurance are defined as follows:
1. Government insurance refers to patients who are covered by government-reimbursed care. In the
United States, this includes Medicare, Medicaid (including all state or federal Medicaid-type
programs), and Veteran’s Administration health plans. (Consider split Medicare/Medicaid.)
2. Commercial refers to all indemnity (fee-for-service) carriers and preferred provider organizations
(PPOs) (e.g., Blue Cross/Blue Shield)
3. HMO refers to a health maintenance organization characterized by coverage that provides
healthcare services for members on a prepaid “capitated” basis.
4. None refers to individuals with no or limited health insurance; thus, the individual is the payer
regardless of ability to pay. Only mark “None” when “self” or “none” is denoted as the first
insurance in the medical record.
(Note: More detailed subcategorization of these broad categories could be considered.)
Prior angina History of angina before the current admission. “Angina” refers to evidence or knowledge of
symptoms before this acute event described as chest pain or pressure, jaw pain, arm pain, or other
equivalent discomfort suggestive of cardiac ischemia. Indicate if angina existed more than 2 weeks
before admission and/or within 2 weeks before admission.
Previous myocardial infarction (MI) The patient has had at least 1 documented previous MI before admission. (For a complete definition,
please refer to “MI” in the “Outcomes” section.) Date should be noted.
Prior congestive heart failure (CHF) History of CHF. “CHF” refers to evidence or knowledge of symptoms before this acute event
described as dyspnea, fluid retention, or low cardiac output secondary to cardiac dysfunction, or the
description of rales, jugular venous distension, or pulmonary edema before the current admission.
Previous percutaneous coronary
intervention (PCI)
Previous PCI of any type (balloon angioplasty, atherectomy, stent, or other) done before the current
admission. Date should be noted.
Previous coronary artery bypass graft
(CABG)
Previous CABG done before the current admission. Date should be noted.
Prior catheterization with stenosis greater
than or equal to 50%
Documented coronary artery disease (CAD) at coronary angiography at any time before the current
admission, with at least a 50% stenosis in a major coronary artery. If the patient had a cardiac
catheterization before the index event that demonstrated a stenosis of 90% and that was successfully
stented to a 0% residual, this should be coded as “yes,” because a stenosis of greater than or equal to
50% was documented.
History of stroke Documented history of stroke or cerebrovascular accident (CVA). Typically, a patient has had a
history of stroke if there was loss of neurological function caused by an ischemic event with residual
symptoms at least 24 hours after onset. The year of the most recent stroke before the current
admission should be noted.
Type of stroke Type of stroke:
1. Hemorrhagic: A stroke with documentation on imaging (e.g., computed tomographic [CT] scan
or magnetic resonance imaging [MRI] of hemorrhage in the cerebral parenchyma, or a subdural or
subarachnoid hemorrhage)
2. Nonhemorrhagic stroke: A focal neurological deficit that results from a thrombus or embolus (and
not due to hemorrhage) that appears and is still partially evident for more than 24 hours
3. Unknown type/no imaging performed: The type of stroke could not be determined by imaging or
other means (lumbar puncture, neurosurgery)
History of transient ischemic attack (TIA) A focal neurological deficit (usually corresponding to the territory of a single vessel) that resolves
spontaneously without evidence of residual symptoms at 24 hours
Peripheral arterial disease Peripheral arterial disease can include the following:
1. Claudication, either with exertion or at rest
2. Amputation for arterial vascular insufficiency
3. Vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
4. Documented aortic aneurysm
5. Positive noninvasive test (e.g., ankle brachial index less than 0.8)
Diabetes History of diabetes, regardless of duration of disease, need for antidiabetic agents, or a fasting blood
sugar greater than 7 mmol/l or 126 mg/dl. If yes, the type of diabetic control should be noted (check
all that apply):
1. None
2. Diet: Diet treatment
3. Oral: Oral agent treatment
4. Insulin: Insulin treatment (includes any combination of insulin)
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ELEMENT DEFINITION
Hypertension Hypertension as documented by:
1. History of hypertension diagnosed and treated with medication, diet, and/or exercise
2. Blood pressure greater than 140 mmHg systolic or 90 mmHG diastolic on at least 2 occasions
3. Current use of antihypertensive pharmacological therapy
Smoking History confirming cigarette smoking in the past. Choose from the following categories:
1. Current: Smoking cigarettes within 1 month of this admission
2. Recent: Stopped smoking cigarettes between 1 month and 1 year before this admission
3. Former: Stopped smoking cigarettes greater than 1 year before this admission
4. Never: Never smoked cigarettes
Dyslipidemia History of dyslipidemia diagnosed and/or treated by a physician. National Cholesterol Education
Program criteria include documentation of the following:
1. Total cholesterol greater than 200 mg/dl (5.18 mmol/l); or
2. Low-density lipoprotein (LDL) greater than or equal to 130 mg/dl (3.37 mmol/l); or,
3. High-density lipoprotein (HDL) less than 40 mg/dl (1.04 mmol/l).
Treatment is also initiated if LDL is greater than 100 mg/dl (2.59 mmol/l) in patients with known
coronary artery disease, and this would qualify as hypercholesterolemia.
Family history of CAD Any direct blood relatives (parents, siblings, children) who have had any of the following at age less
than 55 years:
1. Angina
2. MI
3. Sudden cardiac death without obvious cause
Chronic lung disease Documented history of chronic lung disease (i.e., chronic obstructive pulmonary disease) or currently
being treated with pharmacological therapy (e.g., inhalers, theophylline, aminophylline, or steroids)
and/or has a forced expiratory volume in 1 second (FEV1) less than 75%, room air pO2 less than
60%, or room air pCO2 greater than 50%
Clinical Presentation
Acute coronary syndrome (ACS) symptom
onset: date and time
● Date and time of the onset of symptoms that prompted the patient to seek medical attention
● Symptom onset refers to the onset of cardiac ischemic symptoms related to this acute event, commonly
appearing as chest pain or pressure, arm or jaw pain, dyspnea, nausea/vomiting, or syncope
● In the event of stuttering symptoms, ACS symptom onset is the time at which symptoms became
constant in quality or intensity
Presentation (to healthcare facility):
date and time
Date and time the patient first presented to the hospital.
Type of admission The categories of type of admission are as follows:
1. Elective (i.e., scheduled more than 24 hours before hospital arrival)
2. Urgent (i.e., through the emergency department, or directly from a physician’s office)
3. Transferred from another facility
Admission location The categories of location of patient at the time of admission to the hospital or observation unit are
as follows:
1. Coronary or intensive care unit (CCU/ICU)
2. Step-down unit/monitored bed/cardiac ward
3. Unmonitored hospital floor
4. Observation unit/emergency department chest pain unit
Means of transport The categories of the means by which the patient was transported to the facility are as follows:
1. Self/family
2. Ambulance
3. Mobile ICU
4. Air (helicopter) transfer from another facility
5. Ambulance transfer from another acute care facility
Killip class Killip class of the patient at the time of hospital admission:
1. Class 1: Absence of rales over the lung fields and absence of S3
2. Class 2: Rales over 50% or less of the lung fields or the presence of an S3
3. Class 3: Rales over more than 50% of the lung fields
4. Class 4: Shock (see also Outcomes section for full definition)
Heart rate Heart rate (beats per minute) should be the recording that was done closest to the time of
presentation to the healthcare facility
Systolic and diastolic blood pressure (at
time of presentation and on discharge)
Supine systolic and diastolic blood pressure (mmHg) should be the recording that was done closest to
the time of presentation to the healthcare facility and on discharge
2119JACC Vol. 38, No. 7, 2001 Cannon et al.
December 2001:2114–30 ACC Clinical Data Standards
ELEMENT DEFINITION
Height Patient’s height in centimeters or inches
Weight Patient’s weight in kilograms or pounds
Angina type Category of patient’s angina type if present (choose one):
I. Atypical chest pain: Pain, pressure, or discomfort in the chest, neck, or arms not clearly
exertional or not otherwise consistent with pain or discomfort of myocardial ischemic origin
II. Stable angina: Angina without a change in frequency or pattern for the 6 weeks before this
procedure. Angina is controlled by rest and/or sublingual/oral/transcutaneous medications.
III. Unstable angina (one of the following criteria is necessary):
1. Angina that occurred at rest and was prolonged, usually lasting more than 20 minutes
2. New-onset angina of at least Canadian Cardiovascular Society (CCS) classification III severity
3. Recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at
least CCS class III
IV. MI: For a complete definition, please refer to “MI” in the “Outcomes” section.
Number of episodes of angina in last 24
hours
Number of distinct episodes of anginal pain that occurred in the last 24 hours before hospital
admission
Secondary cause of angina (yes/no) Note whether the angina was precipitated by a secondary factor such as fever, anemia, hypoxemia,
tachycardia, thyrotoxicosis, or severe valvular disease, as defined by Braunwald (33)
ECG Findings
First 12-lead ECG: date and time Note date and time the first 12-lead ECG was performed for acute episode (whether in a prehospital
setting, emergency department, or inpatient unit).
Location of ECG changes The location of each type of ECG change listed below can be broken into 4 categories:
1. Inferior leads: II, III, aVF
2. Anterior leads: V1 to V4
3. Lateral leads: I, aVL, V5 to V6
4. True posterior: (relevant only for tall R waves) V1 V2
Consideration can be given to recording posterior ST-segment changes (if applicable), the maximal
amount of ST-segment changes, and/or the number of leads with ST-segment changes.
Type of ECG changes 1. ST-segment elevation indicates greater than or equal to 1 mm (0.1 mV) elevation in 2 or more
contiguous leads
2. ST-segment depression of at least 0.5 mm (0.05 mV) in 2 or more contiguous leads (includes
reciprocal changes)
3. T-wave inversion of at least 1 mm (0.1 mV) including inverted T waves that are not indicative of
acute MI
4. Q waves refer to the presence of Q waves that are greater than or equal to 0.03 seconds in width
and greater than or equal to 1 mm (0.1 mV) in depth in at least 2 contiguous leads
Bundle-branch block (BBB) and type The presence of left or right BBB should be noted, as well as whether it is new, old, or of uncertain
timing
Rhythm The categories of rhythm are as follows:
1. Sinus rhythm
2. Atrial fibrillation (or flutter)
3. Paced
4. Other rhythm (e.g., ventricular tachycardia, supraventricular tachycardia)
ST elevation in lead V4R If right-sided precordial leads are performed, the presence or absence of ST-segment elevation greater
than or equal to 1 mm (0.1 mV) in lead V4R should be noted
Follow-up ECG: new Q waves If a follow-up ECG is performed (at least 6 hours after the initial ECG, the presence or absence of
new Q waves that are greater than or equal to 0.03 seconds in width, in at least 2 contiguous leads,
and greater than or equal to 1 mm (0.1 mV) in depth not seen on initial ECG should be noted.
Laboratory Tests
Creatine kinase (CK)
● Upper limit of normal The upper limit of normal of total CK as defined by individual hospital laboratory standards. The
units of the CK and type of units (e.g., IU, ng/dl, kCat/l) should be noted.
● All values All CK values during the hospitalization should be noted; include the units, date, and time
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ELEMENT DEFINITION
CK-MB
● Upper limit of normal The upper limit of normal of CK-MB as defined by individual hospital laboratory standards. The
units of the CK-MB and type of units (e.g., IU, %, index, ng/dl, kCat/l) should be noted.
● All values All MB values during the hospitalization should be noted; include the units, date, and time
Troponin T or troponin I
● Troponin type Indicate which type:
T or I
● Upper limit of normal Indicate the upper limit of normal (usually the 99th percentile of a normal population) and the units
(e.g., ng/dl)
● All values All troponin T or I values during the hospitalization should be noted; include units, date, and time
Other labs
● Total serum cholesterol level The first total serum cholesterol level and type of units should be noted
● LDL First serum low density lipoprotein (LDL) and units (either calculated or direct, if measured)
● HDL First serum high density lipoprotein (HDL) level and units
● C-reactive protein First serum C-reactive protein level and units
● Serum creatinine First creatinine level and units
● Hemoglobin A1c Documented laboratory value and units for patient’s hemoglobin A1c
Cardiac Procedures
Stress test Indicate whether an exercise tolerance or pharmacological stress test was performed during the
hospital stay. Date should be noted.
● ECG alone, or either radionuclide
imaging or echocardiogram
Indicate if the test involved only ECG monitoring, or included either radionuclide (perfusion)
imaging (e.g., thallium, Sestamibi), or echocardiography
● Maximal or submaximal Maximal stress test (symptom limited) or submaximal test (e.g., modified Bruce protocol ending with
stage 1 or stage 2)
● Ischemia result (positive, negative,
equivocal)
1. Positive: On an exercise tolerance test, the patient developed either:
a. Both ischemic discomfort and ST shift greater than or equal to 1 mm (0.1 mV) (horizontal or
downsloping) or
b. New ST shift greater than or equal to 2 mm (0.2 mV) (horizontal or downsloping) believed to
represent ischemia even in the absence of ischemic discomfort
If the patient had an equivalent type of exercise test (e.g., exercise thallium or MIBI test, stress
echocardiography, or dipyridamole, thallium, or adenosine radioisotope scan) that showed definite
evidence of ischemia (e.g., an area of clear reversible ischemia), this should be considered a positive test.
2. Negative: No evidence of ischemia (i.e., no typical angina pain and no ST shifts).
3. Equivocal: Either:
a. Typical ischemic pain but no ST shift greater than or equal to 1 mm (0.1 mV) (horizontal or
downsloping) or
b. ST shift of 1 mm (0.1 mV) (horizontal or downsloping) but no ischemic discomfort
● Imaging testing Note presence or absence of a fixed defect indicating an old MI
Ejection fraction (EF) The first EF obtained during the hospital stay. It is the percent of blood emptied from the ventricle
at the end of contraction and can be obtained, in preferred order, from a left ventriculogram,
radionuclide ventriculography, or echocardiogram. If only a range is estimated for EF, the midpoint
of the range should be the value noted.
EF test Note type of test used for EF:
1. Contrast ventriculography
2. Radionuclide ventriculography
3. Echocardiography
Note also whether it was estimated or calculated.
Cardiac catheterization/angiography Diagnostic cardiac catheterization/angiography performed during the hospital stay. Date should be noted.
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Maximum stenosis by vessel (left anterior
descending coronary artery [LAD], left
circumflex [LCx], right coronary artery
[RCA], left main [LM], graft)
Stenosis represents the percentage occlusion, from 0 to 100%, associated with the identified vessel
systems. Percent stenosis at its maximal point is estimated to be the amount of reduction in the
diameter of the “normal” vessel proximal to the lesion. For the denominator, take the maximum
internal lumen diameter proximal and distal to the lesion. In instances where multiple lesions are
present, enter the highest percentage stenosis noted. The systems of interest are as follows and should
include major branch vessels of greater than 2 mm diameter:
● Greatest stenosis assessed in the LAD or any major branch vessel
● Greatest stenosis assessed in the LCx or any major branch vessel
● Greatest stenosis assessed in the RCA or any major branch vessel
● Greatest stenosis assessed in the LM
● Greatest stenosis assessed in bypass graft
Culprit artery Vessel considered to be responsible for the ACS. The investigator should use his/her judgment in
choosing the primary vessel. In cases in which this is difficult to determine (despite correlation of
ECG changes and angiographic data), the vessel supplying the largest territory of myocardium should
be selected:
● LAD
● LCx
● RCA
● LM
● Graft
● Unknown
Note: “None” should be considered if there is no apparent coronary vessel lesion that could be
responsible for evidence of ischemia.
Culprit artery TIMI flow TIMI grade flow in the culprit artery is defined as follows:
1. Grade 0 (no perfusion): There is no antegrade flow beyond the point of occlusion
2. Grade 1 (penetration without perfusion): The contrast material passes beyond the area of
obstruction but “hangs up” and fails to opacify the entire coronary bed distal to the obstruction for
the duration of the cineangiographic filming sequence
3. Grade 2 (partial perfusion): The contrast material passes across the obstruction and opacifies the
coronary bed distal to the obstruction. However, the rate of entry of contrast material into the
vessel distal to the obstruction or its rate of clearance from the distal bed (or both) is perceptibly
slower than its entry into or clearance from comparable areas not perfused by the previously
occluded vessel (e.g., the opposite coronary artery or the coronary bed proximal to the obstruction)
4. Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction occurs as
promptly as antegrade flow into the bed from the involved bed and is as rapid as clearance from
an uninvolved bed in the same vessel or the opposite artery
PCI PCI performed. Date should be noted.
Time of first balloon inflation Time of the first balloon inflation or stent placement. If the exact time of first balloon inflation or
initial stent (if no balloon) placement is not known, the time of the start of the procedure should be
indicated.
PCI status Note the status of the PCI using the following categories:
I. Elective: The procedure could be deferred without increased risk of compromised cardiac
outcome
II. Urgent: All of the following conditions are met:
A. Not elective
B. Not emergency
C. Procedure required during same hospitalization to minimize chance of further clinical
deterioration
III. Emergency: The patient’s clinical status includes any of the following:
A. Ischemic dysfunction (any of the following)
1. Ongoing ischemia including rest angina despite maximal medical therapy (medical and/or
intra-aortic balloon pump [IABP]
2. Acute evolving MI within 24 hours before intervention
3. Pulmonary edema requiring intubation
B. Mechanical dysfunction (either of the following):
1. Shock with circulatory support
2. Shock without circulatory support
IV. Salvage: The patient is undergoing CPR en route to the catheterization laboratory
Number of lesions attempted Number of lesions into which an attempt was made to pass a guidewire, whether successful or not
Number of stents placed Number of stents placed
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Number of lesions successfully dilated Number of lesions in which residual postintervention stenosis is less than 50% of the arterial luminal
diameter, TIMI flow is 3, and the minimum decrease in stenosis is 20%
Glycoprotein (GP) IIb/IIIa blockade Whether GP IIb/IIIa was used, and if so, when initial dose was first administered:
● Before cateterization laboratory visit
● Immediately preceding PCI
● During PCI, but after initial balloon inflation
● After catheterization laboratory visit
● Contraindicated
Note the exact drug used. Available drugs are abciximab, eptifibatide, tirofiban, trial-based agent (not
listed above or randomized blindly between 2 agents), other.
CABG CABG procedure performed during this admission. Date should be noted.
IABP IABP used during this admission
Pulmonary artery catheter Pulmonary artery (Swan Ganz) catheter used during this admission
Temporary pacemaker Temporary pacemaker placed during this admission
Permanent pacemaker Permanent pacemaker placed during this admission
Ventilator Intubation and need for respiratory support on a ventilator
Medications For all the medications listed below, their use at 3 time points should be noted:
1. Before hospital admission (i.e., chronic therapy)
2. During the first 24 hours after hospital admission (which does include medications given in the
immediate prehospital [ambulance] setting)
3. Hospital discharge
For selected medications, contraindications should be noted.
Fibrinolytic therapy Fibrinolytic therapy administered. Note the exact drug used.
Date and time fibrinolytic therapy initiated Date and time the intravenous (IV) fibrinolytic was initiated. If initiated by a bolus dose, note date
and time the initial bolus was administered.
● Fibrinolytic therapy—contraindications 1. Previous hemorrhagic stroke at any time; other strokes or cerebrovascular events within 1 year
2. Known intracranial neoplasm
3. Active or recent (within 2 to 4 weeks) internal bleeding (does not include menses)
4. Suspected aortic dissection
5. Severe uncontrolled hypertension on presentation (blood pressure 180/110 mmHg). Note: This
could be an absolute contraindication in low-risk patients with MI.
6. History of prior CVA or known intracerebral pathology not covered in contraindications
7. Current use of anticoagulants in therapeutic doses (INR greater than or equal to 2); known
bleeding diathesis
8. Recent trauma (within 2 to 4 weeks), including head trauma, traumatic or prolonged (greater than
10 minutes) CPR, or major surgery (less than 3 weeks)
9. Pregnancy
IV nitrate Nitroglycerin was administered intravenously
Nitrates (oral or topical) Oral or topical nitroglycerin was administered. Commonly prescribed agents include isosorbide
dinitrate, isosorbide mononitrate, Nitro-Dur transdermal infusion system, or nitroglycerin paste.
Sublingual nitroglycerin or nitroglycerin spray used on an as-needed basis only should not be noted in
this category.
IV beta-blockers IV beta-blockers administered. Some forms of IV beta-blockers include atenolol, metoprolol,
propranolol, timolol, esmolol, and labetalol.
Oral beta-blockers Oral beta-blockers administered. Some generic forms of oral beta-blockers include atenolol,
metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol, bucindolol, bisoprolol, labetalol, and
carvedilol.
● Beta-blockers—contraindications 1. Allergy or history of intolerance
2. Bradycardia (heart rate less than 60 beats per minute)
3. Symptomatic acute heart failure
4. Systolic blood pressure of less than 100 mmHg
5. PR interval greater than 0.24 seconds
6. 2nd- and 3rd-degree heart block or bifascicular heart block
7. Asthma
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Calcium channel blockers Calcium channel blockers administered. Some generic forms of calcium channel blockers include
verapamil, nifedipine, diltiazem, nicardipine, nimodipine, nisoldipine, felodipine, and amlodipine.
Aspirin Aspirin administered
● Aspirin—contraindications 1. True allergy to aspirin
2. Active bleeding
Clopidogrel/ticlopidine Clopidogrel or ticlopidine administered
Other antiplatelet agents Another antiplatelet agent, not listed above, administered (e.g., dipyridamole)
GP IIb/IIIa blockers GP IIb/IIIa blockers administered. Note the exact drug used. Available drugs are abciximab,
eptifibatide, tirofiban, trial-based GP IIb/IIIa blocker (i.e., not listed above or randomized blindly
between 2 agents), or other.
Antithrombin agents Antithrombin agent administered. Available drugs are unfractionated heparin, low-molecular-weight
heparin (enoxaparin, dalteparin, nadroparin, danaparoid, hirudin, and bivalirudin), trial-based
antithrombin agent (i.e., not listed above or randomized blindly between 2 agents), or other.
Warfarin Warfarin (or coumarol, coumarin) administered
Female hormone replacement therapy Female hormone replacement therapy administered
Nicotine replacement therapy Nicotine replacement agents administered (e.g., buproprion)
Antiarrhythmics Antiarrhythmic drug administered. Some common drugs are amiodarone, sotalol, quinidine,
procainamide, and lidocaine.
ACE inhibitors ACE inhibitors administered. Some common generic forms include captopril, enalapril, lisinopril, and
ramipril.
● ACE inhibitors—contraindications 1. Allergy or intolerance (e.g., cough) to ACE inhibitors
2. Moderate to severe aortic stenosis
3. Bilateral renal artery stenosis
4. History of angioedema, hives, or rash in response to ACE inhibitors
5. Hyperkalemia
6. Symptomatic hypotension
7. Severe renal dysfunction
Angiotensin II receptor blocker (ARB) ARBs administered. Common forms are losartan, valsartan, and candesartan.
Diuretics Diuretics administered. Some commonly prescribed agents are furosemide, ethacrynic acid,
hydrochlorothiazide, spironolactone, metolazone, and bumetanide.
Digitalis Digitalis administered. Some common generic forms include digoxin and digitoxin.
Lipid-lowering agents Lipid-lowering agent administered. Note the type of agent:
1. Statin (HMG Co-A reductase inhibitors)
2. Fibrates
3. Nicotinic acid
4. Resin drugs
5. Other
Frequently prescribed drugs are atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin,
cholestyramine, colestipol, probucol, and gemfibrozil.
Outcomes
Death Patient died during this hospitalization. Date should be noted.
MI To meet the criteria as a postadmission event, an MI must be distinct from the index event at the
time of admission (i.e., reinfarction for a patient who was admitted to the hospital with an MI). Date
and time should be noted.
MI is defined by the ESC/ACC definition below. In addition 2 different subcategorizations of MI
are further specified as follows:
1. ST vs. non–ST-segment elevation MI
a. ST-elevation MI vs.
b. Non–ST-elevation MI vs.
c. BBB/uncertain
And
2. Q-wave vs. non–Q-wave MI
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MI (continued) a. Q wave
b. Non-Q-wave MI
c. BBB/Uncertain
ESC/ACC DEFINITION OF MI (15)
Either one of the following criteria satisfies the diagnosis for an acute, evolving, or recent MI:
1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical
markers of myocardial necrosis (see further description of *Biochemical Marker Evidence of MI
below) with at least 1 of the following:
a. Ischemic symptoms
b. Development of pathological Q waves on the ECG (for further description, see ‡Classification
of Q-Wave vs. Non–Q-Wave MI below)
c. ECG changes indicative of ischemia (ST-segment elevation or depression; for further
description, see †Classification of STEMI vs. Non-STEMI)
d. Coronary artery intervention (e.g., coronary angioplasty)
Or
2. Pathological findings of an acute MI
* Biochemical marker evidence of MI. The following are biochemical indicators for detecting
myocardial necrosis (see below for a definition of reference control limits):
1. Troponin T or I: Maximal concentration of troponin T or I greater than the MI decision limit
on at least 1 occasion during the first 24 hours after the index clinical event
2. CK-MB:
a. Maximal value of CK-MB, preferably CK-MB mass, greater than upper limit of normal on 2
successive samples
b. Maximal value of CK-MB greater than 2 times the upper limit of normal on 1 occasion
during the first hours after the index clinical event
Or
3. Total CK: In the absence of availability of a troponin or CK-MB assay, total CK greater than 2
times the upper limit of normal, or the B fraction of CK may be used, but these last 2
biomarkers are considerably less satisfactory than CK-MB
Defining reference control values (MI diagnostic limit and upper limit of normal): Reference values
must be determined in each laboratory by studies using specific assays with appropriate quality
control, as reported in peer-reviewed journals. Acceptable imprecision (coefficient of variation) at
the 99th percentile for each assay should be defined as less than or equal to 10%. Each individual
laboratory should confirm the range of reference values in their specific settings.
Special circumstances (for all types of MI):
● For patients with admission MI, the CK-MB value associated with the recurrent MI must be
increased by at least 50% of the previous value (i.e., a re-elevation of cardiac markers)
● For patients with MI within 24 hours after PCI, the CK-MB (or CK if MB not available) must
be greater than or equal to 3 times the upper limit of normal. No ECG changes or symptoms are
required.
● For patients with MI within 24 hours after CABG, the CK-MB (or CK if MB not available) must
be greater than or equal to 5 times the upper limit of normal, and new Q waves must be present
as defined above, or CK-MB value must be greater than or equal to 10 times the upper limit of
normal (with or without Q waves). No symptoms are required.
● For patients who die and for whom no cardiac markers were obtained, the presence of new ST-
segment elevation and new chest pain would meet criteria for MI
† Classification of ST-elevation MI (STEMI) vs. non-STEMI. The patient should manifest a
typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers
of myocardial necrosis (see “Biochemical marker evidence of MI” above), and
1. STEMI. ST-segment elevation: New or presumed new ST-segment elevation at the J point in 2
or more contiguous leads with the cutoff points greater than or equal to 0.2 mV in leads V1,
V2, or V3, or greater than or equal to 0.1 mV in other leads
Or
2. NSTEMI. Either of the following (in the absence of ST elevation):
a. ST-segment depression or T-wave abnormalities
b. Ischemic symptoms in the presence or absence of chest discomfort. Ischemic symptoms may
include:
(1) unexplained nausea and vomiting or diaphoresis
(2) persistent shortness of breath secondary to left ventricular failure
(3) unexplained weakness, dizziness, lightheadedness, or syncope
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MI (continued) Or
3. BBB/uncertain type: Either of the following:
a. Left BBB (new or old) or paced rhythm that obscures assessment of ST elevation. (If definite
new ST elevation can be identified compared with an old ECG, then STEMI should be the
classification.)
b. If the initial ECG findings are not available or the patient presents beyond the time of ST-
segment changes (e.g., greater than 24 hours), classify as uncertain type
‡ Classification of Q-wave vs. non–Q-wave MI. The patient should manifest the typical rise and
gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial
necrosis (see “Biochemical marker evidence of MI” above), and
1. Q-wave MI: Development of any Q wave in leads V1 through V3, or the development of a Q wave
greater than or equal to 30 ms (0.03 s) in leads I, II, aVL, aVF, V4, V5, or V6. (Q-wave changes
must be present in any 2 contiguous leads and be greater than or equal to 1 mm in depth.)
Or
2. Non–Q-wave MI: The absence of new Q waves as defined above on ECGs performed at least
12 hours after the event
Or
3. BBB/uncertain type of MI: Left BBB (new or old) or paced rhythm that obscures assessment of
Q waves
Recurrent rest angina with ECG changes Recurrent ischemic pain occurring at rest (and believed to be cardiac in origin) with associated ECG
changes
Recurrent rest angina without ECG
changes
Recurrent ischemic pain occurring at rest (and believed to be cardiac in origin) without associated
ECG changes
Bleeding (TIMI major, TIMI minor, or
none)
An episode of bleeding is defined by the TIMI criteria as:
1. Major: Overt clinical bleeding (or documented intracranial or retroperitoneal hemorrhage)
associated with a drop in hemoglobin of greater than 5 g/dl (0.5 g/l) or in hematocrit of greater
than 15% (absolute)
Note: A patient who experiences an intracranial hemorrhage should be considered to have a major
hemorrhage.
2. Minor: Overt clinical bleeding associated with a fall in hemoglobin of 3 to less than or equal to 5
g/dl (0.5 g/l) or in hematocrit of 9% to less than or equal to 15% (absolute)
3. None: No bleeding event that meets the major or minor definition
Note: In calculating the fall in hemoglobin or hematocrit, a transfusion of whole blood or packed
red blood cells is counted as 1 g/dl (0.1 g/l) hemoglobin or 3% absolute in hematocrit. This would
be in addition to the actual fall in hemoglobin or hematocrit.
Location of bleeding Categories for the location of bleeding are:
● cardiac catheterization site
● CABG surgical site (e.g., chest tubes, sternal wound)
● other instrumented site
● gastrointestinal site
● other (noninstrumented) site
Transfusion Transfusion of either whole blood or packed red blood cells due to a hemorrhagic event. Note the
number of units transfused.
Stroke A stroke or CVA with loss of neurological function caused by an ischemic or hemorrhagic event with
residual symptoms at least 24 hours after onset or leading to death
Type of stroke Indicate the type of stroke:
1. Hemorrhagic: A stroke with documentation on imaging (e.g., CT scan or MRI of hemorrhage in
the cerebral parenchyma, or a subdural or subarachnoid hemorrhage). Evidence of hemorrhagic
stroke obtained from lumbar puncture, neurosurgery, or autopsy can also confirm the diagnosis.
2. Nonhemorrhagic: A focal neurological deficit that results from a thrombus or embolus (and not
due to hemorrhage) that appears and is still partially evident for more than 24 hours
3. Unknown/no imaging performed: if the type of stroke could not be determined by imaging or
other means (from lumbar puncture, neurosurgery, or autopsy)
Transient ischemic attack (TIA) A focal neurological deficit (usually corresponding to the territory of a single cerebral vessel) that
resolves spontaneously without any evidence of residual deficit at 24 hours
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Thrombocytopenia Platelet count dropped to either less than 50,000/mm3 or between 50,000 and less than
100,000/mm3; the level should be noted. This platelet count should be confirmed as not being
pseudothrombocytopenia (i.e., platelet clumping in citrated blood).
CHF Developed evidence of new CHF after admission
● None (absence of rales over the lung fields)
● Mild CHF (rales over 50% or less of the lung fields). Evidence of new pulmonary vascular
congestion on chest radiograph also meets the definition.
● Severe CHF (rales over more than 50% of the lung fields). Evidence of pulmonary edema on chest
radiograph would also meet this definition.
Cardiogenic shock Experienced cardiogenic shock. Clinical criteria for cardiogenic shock are hypotension (a systolic
blood pressure of less than 90 mmHg for at least 30 minutes or the need for supportive measures to
maintain a systolic blood pressure of greater than or equal to 90 mmHg), end-organ hypoperfusion
(cool extremities or a urine output of less than 30 ml/h, and a heart rate of greater than or equal to
60 beats per minute). The hemodynamic criteria are a cardiac index of no more than 2.2 l/min per
square meter of body-surface area and a pulmonary-capillary wedge pressure of at least 15 mmHg (34).
Cardiac rupture/ventricular septal defect Rupture of the ventricular myocardium, as documented by cardiac echocardiography,
ventriculography, pericardiocentesis, cardiac surgery, and/or autopsy. Rupture could be of the free wall
or the ventricular septum. Included in this category is frank papillary muscle rupture.
Atrial arrhythmia A new episode or acute recurrence of atrial arrhythmia documented by 1 of the following:
1. Atrial fibrillation/flutter
2. Supraventricular tachycardia requiring treatment (supraventricular tachycardia that requires
cardioversion, drug therapy, or is sustained for greater than 1 minute)
Ventricular arrhythmia Ventricular tachycardia or ventricular fibrillation requiring cardioversion and/or intravenous
antiarrhythmics
High-degree atrioventricular (AV) block High-level AV block defined as third-degree AV block or second-degree AV block with bradycardia
requiring pacing
Date of discharge Date the patient was discharged from the acute care hospital. If the patient died in the hospital, the
hospital discharge date is the date of death.
Discharge destination Location the patient was discharged to upon leaving this hospital. The choices are:
1. Home
2. Nursing home or personal care residence
3. Another nonacute care or rehabilitation hospital
4. Another acute care hospital
5. Death in hospital
Smoking cessation counseling Advice or a pamphlet was given or a discussion was conducted with the patient (by physician, nurse,
or other personnel) regarding the importance of stopping smoking
Weight management counseling Advice given or counseling conducted by a physician or nurse in patients greater than 120% of ideal
weight for height. Particular emphasis for weight loss may be given for patients with hypertension,
elevated triglycerides, or elevated glucose levels.
Diet counseling Advice given or discussion conducted by a physician or nurse encouraging diet counseling. This can
include low cholesterol foods; moderate sodium restriction; emphasis on fruits, vegetables, and low-fat
dairy products; and increased consumption of omega-3 fatty acids.
Exercise counseling Advice given or discussion conducted by a physician or nurse encouraging patients to engage in a
minimum of 30 to 60 minutes of physical activity daily or at least 3 to 4 times weekly.
Cardiac rehabilitation Advice given or discussion conducted with the patient (by physician, nurse, or other personnel)
regarding the importance of joining a cardiac rehabilitation program, or an appointment made
Days in ICU Total number of days the patient spent in an intensive care bed at the index hospital only, either
consecutively or intermittently. To count days:
1. Find the ICU/CCU admit date/time and the date/time patient was transferred out to another unit
(telemetry or unmonitored bed)
2. For every 24-hour period, count 1 day
3. For any partial day remaining, round up if greater than or equal to 12 hours and round down if
less than 12 hours
In the case of an in-hospital infarct in which the patient is already in an intensive care bed, record
the number of days spent in ICU/CCU after the diagnosis of MI was made.
Final diagnosis of the admission event The final diagnosis for the event that prompted admission:
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1. STEMI is defined as an ACS in which there is cardiac marker evidence of myocardial necrosis
(e.g., positive CK-MB) and new (or presumably new if no prior ECG is available) ST-segment
elevation on the admission ECG. (For a complete definition, please refer to “MI” in the
“Outcomes” section.)
2. NSTEMI is defined as an ACS in which there is cardiac marker evidence of myocardial necrosis
(e.g., positive CK-MB or troponin) without new ST-segment elevation. (For a complete
definition, please refer to “MI” in the “Outcomes” section.)
3. BBB/uncertain type. For a complete definition, please refer to “MI” in the “Outcomes” section.
4. Unstable angina is defined as angina pectoris (or equivalent type of ischemic discomfort) with any
1 of the 3 following features:
a. Angina occurring at rest and prolonged, usually greater than 20 minutes
b. New-onset angina of at least CCS classification III severity
c. Recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at
least CCS class III
The patient must also not have any biochemical evidence of necrosis.
a. Definite/probable unstable angina: Patients with clinical history consistent with the diagnosis of
unstable angina as described above, in whom ischemia has been confirmed by the presence of
ST-segment changes on the initial ECG or in association with recurrent rest pain, by a positive
stress test, or by the presence of small elevations of troponin that do not meet criteria for MI
b. Possible unstable angina is present when an acute ischemic process has not been excluded as a
possible cause of the presenting symptoms, or the clinical history is consistent with unstable
angina but no diagnostic test (noted above) was performed to confirm the diagnosis
5. Stable CAD: The patient has a clinical diagnosis or prior history of CAD, but after evaluation in
the hospital, the episode of discomfort was not thought to have represented unstable angina
6. Noncardiac chest pain: Pain in the chest, neck, or arms or abdomen (or other clinical
manifestation) not clearly exertional or not otherwise consistent with pain or discomfort of
myocardial ischemic origin
Examples:
1. If a patient was admitted with rest pain but had negative cardiac markers, then on day 3
developed recurrent pain, and it was determined that an MI had occurred, the event prompting
admission should be coded as “unstable angina” here. The MI on day 3 should be recorded in the
“Outcomes” section as a postadmission MI.
2. If a patient was admitted with rest pain and initial cardiac markers were negative, but the enzymes
drawn over the subsequent 24 hours became positive, this is most consistent with an NSTEMI as
the admission event.
Follow-up Measures These elements are believed to be the most important outcomes to monitor in patients with ACS. The timing
could be flexible, but the most common time points are 30 days, 6 months, and/or 1 year.
Death The patient died since the previous visit/contact. This category includes all deaths regardless of cause
of death.
● Primary cause (cardiovascular vs.
noncardiovascular)
1. Cardiovascular death indicates cause of death was sudden cardiac death, MI, unstable angina, or
other CAD; vascular death (e.g., stroke, arterial embolism, pulmonary embolism, ruptured aortic
aneurysm, or dissection); CHF; or cardiac arrhythmia
2. Noncardiovascular death indicates cause of death was respiratory failure, pneumonia, cancer,
trauma, suicide, or any other already defined cause (e.g., liver disease or renal failure)
MI Documented evidence of an MI. For a complete definition, please refer to “MI” in the “Outcomes”
section.
Cardiac catheterization Cardiac catheterization (with or without revascularization) procedure performed since the previous
visit/contact
PCI PCI performed since the previous visit/contact
CABG CABG performed since the previous visit/contact
Readmission Readmission to a hospital
Readmission reason Reasons for admission (include all that apply):
1. MI (documented)
2. Unstable angina
3. Angina (without MI)
4. PCI
5. CABG
6. CHF (without MI)
7. Arrhythmia or conduction disturbance (without MI)
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8. Other cardiovascular problem
9. Noncardiovascular problem
Angina status CCS classes of angina (35):
I. Ordinary physical activity (for example, walking or climbing stairs) does not cause angina; angina
occurs with strenuous or rapid or prolonged exertion at work or recreation
II. Slight limitation of ordinary activity (for example, angina occurs walking or stair climbing after
meals, in cold, in wind, under emotional stress, or only during the few hours after awakening;
walking more than 2 blocks on the level or climbing more than 1 flight of ordinary stairs at a
normal pace; and in normal conditions)
III. Marked limitation of ordinary activity (for example, angina occurs with walking 1 or 2 blocks on
the level or climbing 1 flight of stairs in normal conditions and at a normal pace)
IV. Inability to perform any physical activity without discomfort; angina syndrome may be present at
rest
Medication use 1. Antiplatelet: Aspirin, clopidogrel, or ticlopidine; other (e.g., dipyridamole)
2. ACE: Some common generic forms include captopril, enalapril, lisinopril, and ramipril
3. Beta-blocker: Some forms of IV beta-blockers include atenolol, metoprolol, propranolol, timolol,
esmolol, and labetalol. Some generic forms of oral beta-blockers include atenolol, metoprolol,
nadolol, pindolol, propranolol, timolol, acebutolol, bucindolol, bisoprolol, labetalol, and carvedilol.
4. Lipid lowering: Type of agent includes statin (HMG Co-A reductase inhibitors), fibrates,
nicotinic acid, resin drugs (cholestyramine). Frequently prescribed drugs are cholestyramine,
colestipol, probucol, gemfibrozil, lovastatin, atorvastatin, simvastatin, fluvastatin, pravastatin, and
cerivistatin.
A complete listing of cardiac medications could also be collected.
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